NeuroMetrix, Inc.’s novel “Quell” wearable pain relief device was chosen for participating in an exclusive group dat the 2015 International Consumer Electronics Show (CES) in Las Vegas earlier this month. Quell was selected as one of four finalists in Engadget’s Best of CES 2015 Digital Health and Fitness category, and C|NET profiled Quell in their CES2015 center.
NeuroMetrix’s proprietary non-invasive neurostimulation technology used in Quell is aimed at providing wearers of the device with relief from chronic pain associated with bodily disorders such as diabetes, sciatica, fibromyalgia, and degenerative knee function. The Quell device is small, lightweight, and designed to be worn 24 hours a day, during daytime activities and in bed at night. Quell is claimed to monitor sleep quality and automatically adjust to ensure the relief needed to sleep soundly.
Quell is essentially a compact, wearable, consumer-level Transcutaneous Electrical Nerve Stimulation (TENS) device, and has been cleared by the FDA for chronic pain management and treatment without a doctor’s prescription; users will also have the option of using their smartphone to automatically track and personalize their Quell-based pain therapy. The company claims users will experience relief in as little as 15 minutes, and that Quell technology works with the wearer’s own body by both stimulating nerves and by blocking pain signals to the brain.
NeuroMetrix expects to begin taking pre-orders for Quell in March for shipment beginning during the second quarter of 2015, at which time presumably support apps for iOS and Android will become available. The Quell device will initially be sold exclusively through doctors’ offices and by online purchase from Neurometrix.
Neurometrix founder, President and Chief Executive Officer Shai N. Gozani, M.D. , Ph.D—author of more than 30 peer-reviewed scientific articles and holder of 25 US and international patents—commented, “Recent studies have shown that chronic nerve pain dramatically reduces the quality of life of people with diabetes. We believe that Quell may help many of these people reclaim their life from chronic pain.” NeuroMetrix says more than 2.5 million patients have benefited from its technologies since being founded by Dr. Gozani in 1996 as a Massachusetts Institute of Technology spin-off.